CS
CPXX

Candriam SCA’s CELATOR PHARMACEUTICALS INC. COMMON STOCK CPXX Stock Holding History

Candriam SCA’s Portfolio CPXX Stock Details CPXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-165,000
Closed -$1.81M – 695
2016
Q1 		$1.81M Buy
+165,000
New +$541K 0.05% 337

Other funds holding CPXX

CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 26.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

Candriam SCA's CPXX Position: Q2 2016 in Review

Candriam SCA sold out of CELATOR PHARMACEUTICALS INC. COMMON STOCK (CPXX) in Q2 2016, closing a stake of 165,000 shares — an estimated $1.81M sold.

Candriam SCA first reported a position in CPXX in Q1 2016 and held it in 1 quarter. The position peaked at $1.81M in Q1 2016. 119 funds tracked by Wall St. Rank hold CPXX as of Q2 2016.

  • Candriam SCA reported no remaining CELATOR PHARMACEUTICALS INC. COMMON STOCK position as of Q2 2016 after selling out during the quarter.
  • Candriam SCA sold 165,000 CELATOR PHARMACEUTICALS INC. COMMON STOCK shares in Q2 2016, an estimated $1.81M.
  • Candriam SCA first reported a position in CELATOR PHARMACEUTICALS INC. COMMON STOCK in Q1 2016 and held it in 1 quarter.
  • Candriam SCA's CELATOR PHARMACEUTICALS INC. COMMON STOCK position peaked at $1.81M in Q1 2016.
  • 119 funds tracked by Wall St. Rank held CELATOR PHARMACEUTICALS INC. COMMON STOCK as of Q2 2016.

Based on Candriam SCA's 13F filing for Q2 2016, filed 26 Jul 2016.